Merck (MRK) Tops Q1 EPS by 31c; Raises Outlook

Merck (NYSE: MRK) reported Q1 EPS of $2.14, $0.31 better than the analyst estimate of $1.83. Revenue for the quarter came in at $15.9 billion versus the consensus estimate of $14.71 billion.

GUIDANCE:

Merck sees FY2022 EPS of $7.24-$7.36, versus the consensus of $7.24. Merck sees FY2022 revenue of $56.9-58.1 billion, versus the consensus of $57.35 billion.

For earnings history and earnings-related data on Merck (MRK) click here.

You May Also Be Interested In

• Stitch Fix (SFIX) Tops Q4 EPS by 4c; Offers Guidance
• U.S. FDA Approves Update to the Label for WINREVAIR™ (sotatercept-csrk) to Include Data from the Phase 3 HYPERION Trial Evaluating Adults Recently Diagnosed with Pulmonary Arterial Hypertension (PAH
• Merck (MRK) Reiterated at Neutral by Cantor Fitzgerald